Retatrutide is a novel triple agonist that simultaneously targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors. By activating these three key receptors, Retatrutide exerts a powerful and synergistic effect on metabolic regulation. It enhances insulin secretion, reduces appetite, promotes fat metabolism, and increases energy expenditure. This multi-receptor action leads to significant improvements in both blood glucose control and body weight reduction. Clinical trials have shown that Retatrutide can lead to substantial weight loss and improved glycemic control, making it a promising therapeutic candidate for obesity and type 2 diabetes. As a synthetic peptide administered via weekly subcutaneous injection.
| Product Name | Retatrutide Peptide |
| Shelf Life | 2 Years |
| Form | Peptide |
| Indication | Weight Loss |
| Dosage | 1mg~12mg/week |
| Active Ingredient | Retatrutide |
| Storage Conditions | Store At 2-25°C |
| Packaging | 10mg/vial, 15mg/vial, 20mg/vial, 30mg/vial, 40mg/vial |
Retatrutide is designed to treat obesity, type 2 diabetes, and related metabolic disorders by activating three important hormone receptors: GLP-1, GIP, and glucagon (GCGR) receptors. Its key functions include:
1. Appetite Suppression
– By stimulating the GLP-1 and GIP receptors, Retatrutide helps reduce hunger and increase satiety, leading to lower food intake.
2. Blood Sugar Regulation
– It enhances glucose-dependent insulin secretion, improving blood sugar control, particularly beneficial for type 2 diabetes patients.
3. Increased Energy Expenditure
– Activation of the glucagon receptor (GCGR) boosts energy burn and fat metabolism, contributing to weight loss.
4. Weight Loss
– Through its triple-agonist mechanism, Retatrutide delivers significant weight reduction, with clinical trials showing up to 24% body weight loss over 48 weeks.
For high value products, please select air shipping and express delivery for safety.
